Iguratimod tablet and preparation method thereof
By adjusting the composition and preparation process of the Ailamad tablets, the problems of poor solubility and high concentration of ethanol used during the granulation process were solved, and good compressibility and in vitro dissolution effect were achieved, environmental pollution, product stability and The original preparation is basically the same.
Patent Information
- Application Number
- CN202311486859.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-09
- Publication Date
- 2024-12-03
AI Technical Summary
Due to its hydrophobic raw materials, the Ailamad tablets have poor solubility, which affects the human body's absorption, and require high concentration of ethanol during the granulation process, which increases the use of organic solvents and environmental pollution.
Using a composition composed of Alamod, microcrystalline cellulose, sodium carboxymethyl starch, sodium dodecyl sulfate, hydroxypropylmethylcellulose and magnesium stearate, the process procedures and parameters are adjusted to achieve no need for high concentration of ethanol. The preparation method is to control particle size and content uniformity, improve solubility and in vivo dissolution effect.
The good compressibility, content uniformity and in vitro dissolution effect of the Ailamod tablets are achieved, the use of high concentrations of ethanol is avoided, environmental pollution is reduced, and the product stability is basically the same as that of the original preparation.
Smart Images

Figure CN119055600A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine preparation and relates to an iguratimod tablet and a preparation method thereof. Background Art
[0002] Aguratimod is a new type of disease-modifying antirheumatic drug that exerts its antirheumatic effect by mainly inhibiting the production of immunoglobulins and inflammatory cytokines. Aguratimod can significantly improve the disease symptoms and inflammatory indicators of patients with rheumatoid arthritis and relieve patients' pain. Aguratimod was originally prepared by Japan's Toyama Chemical. Toyama Chemical and Japan's Eisai submitted an application for the marketing of Aguratimod tablets in Japan in August 2011, and in June 2012, it was approved for the treatment of rheumatoid arthritis (RA) with a specification of 25 mg and a trade name of Kolbet / Careram. In China, in January 2008, Innovent Biologics completed the clinical study of Aguratimod tablets and submitted an NDA to the State Drug Administration. In August 2011, it was approved for marketing with a trade name of Edesin and a specification of 25 mg. The approved indication is active rheumatoid arthritis.
[0003] Since Iguratimod is a hydrophobic raw material, its solubility ratio is low and its dissolution in the body is poor, which affects the amount of absorption by the human body. At the same time, due to its properties, its granulation performance is relatively poor. At present, during the production and granulation process of Iguratimod, high-concentration ethanol is often added for granulation, which increases the use of organic solvents. The workshop must meet the explosion-proof performance, and also increases the emission of organic gases in the environment. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides an iguratimod tablet and a preparation method thereof. The preparation method does not require the use of high-concentration ethanol, and its parameters such as compressibility, content uniformity, and in vitro dissolution can achieve good technical effects.
[0005] The technical solution provided by the present invention is as follows:
[0006] Disclosed is an iguratimod tablet preparation, which mainly consists of iguratimod, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, hypromellose and magnesium stearate.
[0007] The invention discloses an iguratimod tablet, which is prepared from the following raw materials in parts by weight: 25 parts of iguratimod, 59.50-80.50 parts of microcrystalline cellulose PH101, 27.20-36.80 parts of sodium starch glycolate, 3.83-5.18 parts of sodium lauryl sulfate, 55.25-74.75 parts of purified water, 1.70-2.30 parts of hypromellose E5, 42.50-57.50 parts of microcrystalline cellulose PH302, and 0.85-1.15 parts of magnesium stearate.
[0008] The particle size of iguratimod in the composition is 20 μm≤D90≤50 μm, and D100≤80 μm.
[0009] The content of iguratimod in the composition is 25 mg.
[0010] The weight ranges of the components in the composition are as follows:
[0011] A method for preparing iguratimod tablets comprises the following steps:
[0012] Iguratimod and microcrystalline cellulose PH101 were shaken to mix for the first premixing and added to the wet granulation pot; sodium lauryl sulfate and sodium carboxymethyl starch were sieved and dispersed and added to the wet granulation pot, stirring was started, and the second premixing was performed;
[0013] Adding a hydroxypropyl methylcellulose E5 solution prepared with purified water to perform wet granulation; adding the wet granules into a preliminarily preheated fluidized bed drying pot to continuously fluidize and dry the wet granules; using a mobile wet-dry granulator to granulate the dried granules to obtain dry granules;
[0014] The dry granules are added into a mixing bin of a hopper, microcrystalline cellulose PH302 and sodium starch glycolate are added in sequence for mixing, and then magnesium stearate is added for total mixing; the total mixed material is tableted using a rotary tablet press to obtain elamod tablets.
[0015] Furthermore, the preparation method of the HPMC E5 solution comprises: slowly adding HPMC E5 to purified water while continuously stirring it to prepare a 2% HPMC solution; stirring the solution at an appropriate speed for not less than 1 hour, and taking it out after it is clear and transparent by naked eye observation.
[0016] Furthermore, the first premixing includes: adding the API into a bag, then adding microcrystalline cellulose PH101 into the bag, tightening the bag mouth, shaking and mixing, and then passing through a 60-mesh sieve for mixing once.
[0017] Furthermore, in the second premixing, the stirring frequency is 240-260 rpm, the shearing speed is 1800-2200 rpm, and the pot cover and the filter bag are knocked regularly during the process to fully mix the premixed materials, and the mixing is carried out for 10 minutes.
[0018] Furthermore, during the wet granulation process, the atomization pressure is turned on at 0.20-0.30 MPa, the stirring is turned on at 340-360 rpm, the shearing is turned on at 1800-2200 rpm, and the liquid addition time is controlled at 15-25 min; after the liquid addition is completed, granulation is continued for 2-8 min with the same parameters.
[0019] Furthermore, the wet particles are added into the preliminarily preheated fluidized bed drying pot, the heating and air supply are turned on, the air supply temperature is set at 60-70°C, the material temperature is set at 40-50°C, and the wet particles are continuously fluidized and dried; the drying loss is continuously monitored during the process, and after drying to a moisture content of ≤5.0%, the material temperature drops to below 40°C and is taken out of the pot.
[0020] Furthermore, the dried granules are granulated using a mobile wet and dry granulator, the sieve aperture is 0.8-1.0 mm, and the granulation frequency is 30 Hz.
[0021] Further, the dry particles were added into the mixing bin of the hopper, and microcrystalline cellulose PH302 and sodium starch glycolate were added in sequence for mixing, the mixing frequency was set to 20 Hz, the mixing time was 20 min, and magnesium stearate was added after completion, and the mixing was continued at the same frequency for 10 min, and the material was discharged after completion.
[0022] Furthermore, in the tableting step, the feeding speed is set to 15-25 rpm, the turntable speed is 10-30 rpm, the tableting hardness is controlled at 80-90 N, the tablet weight difference is controlled at ±5%, and the friability is controlled within 1%.
[0023] The preparation process of the iguratimod tablets is as follows:
[0024] Components Weight range (mg / tablet) Ailamode 25.00 Microcrystalline Cellulose PH101 59.50-80.50 Sodium starch glycolate 27.20-36.80 Sodium Lauryl Sulfate 3.83-5.18 Purified water 55.25-74.75 Hydroxypropyl methylcellulose E5 1.70-2.30 Microcrystalline Cellulose PH302 42.50-57.50 Magnesium Stearate 0.85-1.15
[0025] (1) Preparation of 2% Hydroxypropyl Methylcellulose Solution
[0026] First weigh the prescribed amount of purified water, and weigh the prescribed amount of Hydroxypropyl Methylcellulose E5. While the purified water is continuously stirred, slowly add Hydroxypropyl Methylcellulose E5 to prepare a 2% Hydroxypropyl Methylcellulose solution. Stir the solution at an appropriate speed for no less than 1 hour, and take it out for use after it is clear and transparent by naked eye.
[0027] (2) SDS sieving and dispersion
[0028] According to the prescription ratio, weigh sodium lauryl sulfate and half of the total prescription sodium carboxymethyl starch, pass through a 60-mesh sieve and mix three times for later use.
[0029] (3) First premixing
[0030] Weigh the prescribed amount of API and add it into the bag. Then weigh about 1 times the amount of microcrystalline cellulose PH101 and add it into the bag. Tighten the bag mouth and perform preliminary shaking to mix. Then pass through a 60-mesh sieve and mix once for use.
[0031] (4) Second premixing
[0032] Add the above-mentioned sieved mixture of SDS and sodium carboxymethyl starch, and the sieved mixture of raw materials and microcrystalline into the pot of the wet granulator, and use the remaining microcrystalline cellulose PH101 to clean the sieves, bags, basins and other utensils that may be stained, and add them into the pot of the granulator. Turn on the stirring at 250rpm and the shear at 2000rpm. During the process, knock the pot cover and filter bag regularly to fully mix the premixed materials and mix for 10 minutes.
[0033] (5) Wet granulation
[0034] Add 2% hydroxypropyl methylcellulose solution to the above mixed materials, open the atomization pressure of 0.20-0.30MPa, start stirring at 350rpm, shear at 2000rpm, and control the liquid addition time to 15-25min. After the addition is completed, continue granulation for 2-8min with the same parameters, and discharge the material for use.
[0035] (6) Drying
[0036] Add the wet granules into the preheated fluidized bed drying pot, turn on the heating and air inlet, set the air inlet temperature to 60-70℃, the material temperature to 40-50℃, and the air inlet flow rate to keep the material in a low-level fluidized state, and continue to fluidize and dry the wet granules. During the process, the drying weight loss is continuously monitored, and after drying to a moisture content of ≤5.0%, the material temperature drops below 40℃ and is taken out of the pot.
[0037] (7) Whole grain
[0038] The dried granules were granulated using a mobile wet and dry granulator, the sieve aperture was 0.8-1.0 mm, and the granulation frequency was 30 Hz.
[0039] (8) Pretreatment of additional auxiliary materials:
[0040] Take magnesium stearate and no less than half of the prescribed amount of sodium starch glycolate, pass them through a 60-mesh sieve respectively, and set aside.
[0041] (9) Total Mixing
[0042] According to the final granule weight, the amount of additional excipients is calculated and weighed according to the prescription ratio. First, add the dry granules into the mixing bin of the hopper of the corresponding volume, add microcrystalline cellulose PH302 and half of the prescription amount of sodium carboxymethyl starch in turn, set the mixing frequency to 20Hz, and the mixing time to 20min. After completion, add magnesium stearate and continue mixing at the same frequency for 10min. After completion, discharge the material for use.
[0043] (10) Tableting
[0044] The theoretical tablet weight is calculated according to the intermediate content, and the total mixed material is tableted using a rotary tablet press. The feeding speed is set to 15-25rpm, the turntable speed is 10-30rpm, and the tablet is pressed according to the calculated tablet weight. The tablet hardness is controlled at 80-90N, the tablet weight difference is controlled at ±5%, and the friability is controlled within 1%.
[0045] Beneficial Effects
[0046] The present invention mainly achieves the effect of increasing solubility and in vivo dissolution absorption by adjusting the process procedures and parameters and controlling the particle size of the raw materials. The present invention also avoids the use of high-concentration ethanol solutions and can achieve a granulation effect similar to that of using ethanol, and its parameters such as compressibility, content uniformity, in vitro dissolution, etc. can all achieve good technical effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 is the dissolution curve of iguratimod tablets in pH 7.8 phosphate buffer medium;
[0048] Figure 2 This is the dissolution curve of Iguratimod tablets in pH 7.4 phosphate buffer medium. DETAILED DESCRIPTION
[0049] Example:
[0050]
[0051] Note 1: Purified water is removed during the process drying process.
[0052] Preparation method:
[0053] (1) Preparation of 2% Hydroxypropyl Methylcellulose Solution
[0054] First weigh the prescribed amount of purified water, and weigh the prescribed amount of Hydroxypropyl Methylcellulose E5. While the purified water is continuously stirred, slowly add Hydroxypropyl Methylcellulose E5 to prepare a 2% Hydroxypropyl Methylcellulose solution. Stir the solution at an appropriate speed for no less than 1 hour, and take it out for use after it is clear and transparent by naked eye.
[0055] (2) SDS sieving and dispersion
[0056] According to the prescription ratio, weigh sodium lauryl sulfate and half of the total prescription sodium starch glycolate, pass through a 60-mesh sieve and mix three times for later use.
[0057] (3) First premixing
[0058] Weigh the prescribed amount of API and add it into the bag. Then weigh about 1 times the amount of microcrystalline cellulose PH101 and add it into the bag. Tighten the bag mouth and perform preliminary shaking to mix. Then pass through a 60-mesh sieve and mix once for use.
[0059] (4) Second premixing
[0060] Add the above-mentioned sieved mixture of SDS and sodium carboxymethyl starch, and the sieved mixture of raw materials and microcrystalline into the pot of the wet granulator, and use the remaining microcrystalline cellulose PH101 to clean the sieves, bags, basins and other utensils that may be stained, and add them into the pot of the granulator. Turn on the stirring at 250rpm and the shear at 2000rpm. During the process, knock the pot cover and filter bag regularly to fully mix the premixed materials and mix for 10 minutes.
[0061] (5) Wet granulation
[0062] Add 2% hydroxypropyl methylcellulose solution to the above mixed materials, open the atomization pressure of 0.20-0.30MPa, start stirring at 350rpm, shear at 2000rpm, and control the liquid addition time to 15-25min. After the addition is completed, continue granulation for 2-8min with the same parameters, and discharge the material for use.
[0063] (6) Drying
[0064] Add the wet granules into the preheated fluidized bed drying pot, turn on the heating and air inlet, set the air inlet temperature to 60-70℃, the material temperature to 40-50℃, and the air inlet flow rate to keep the material in a low-level fluidized state, and continue to fluidize and dry the wet granules. During the process, the drying weight loss is continuously monitored, and after drying to a moisture content of ≤5.0%, the material temperature drops below 40℃ and is taken out of the pot.
[0065] (7) Whole grain
[0066] The dried granules were granulated using a mobile wet and dry granulator, the sieve aperture was 0.8-1.0 mm, and the granulation frequency was 30 Hz.
[0067] (8) Pretreatment of additional auxiliary materials:
[0068] Take magnesium stearate and no less than half of the prescribed amount of sodium starch glycolate, pass them through a 60-mesh sieve respectively, and set aside.
[0069] (9) Total Mixing
[0070] According to the final granule weight, the amount of additional excipients is calculated and weighed according to the prescription ratio. First, add the dry granules into the mixing bin of the hopper of the corresponding volume, add microcrystalline cellulose PH302 and half of the prescription amount of sodium carboxymethyl starch in turn, set the mixing frequency to 20Hz, and the mixing time to 20min. After completion, add magnesium stearate and continue mixing at the same frequency for 10min. After completion, discharge the material for use.
[0071] (10) Tableting
[0072] The theoretical tablet weight is calculated according to the intermediate content, and the total mixed material is tableted using a rotary tablet press. The feeding speed is set to 15-25rpm, the turntable speed is 10-30rpm, and the tablet is pressed according to the calculated tablet weight. The tablet hardness is controlled at 80-90N, the tablet weight difference is controlled at ±5%, and the friability is controlled within 1%.
[0073] Study on the properties of particles and powders
[0074] The above prescription was used for the preparation and investigation of the prescription, and the relevant parameters were compared with the domestic original research:
[0075] The angle of repose, bulk density, tap density, Carr's index, particle size distribution and other data were tested, and the experimental data showed that the powder in this embodiment had excellent powder properties, good fluidity and compressibility.
[0076] Angle of repose, bulk density, tap density, Carr index
[0077]
[0078]
[0079] Determine its particle size distribution
[0080] Particle size distribution >60 mesh 60-100 mesh 100-150 mesh 150-200 mesh <200th Example 1 1.0% 2.5% 30.0% 33.6% 32.8% Example 2 1.5% 1.9% 31.6% 40.4% 24.7% Example 3 1.9% 1.1% 34.3% 36.8% 25.9%
[0081] Investigation on the uniformity of mixing of total mixed materials
[0082] The data of the total mixing uniformity inspection of the embodiment show that the total mixing materials of the present embodiment can be mixed uniformly with good uniformity.
[0083]
[0084] Comparison of content uniformity with the original formulation
[0085] Relevant search information shows that the original preparation may use about 50% ethanol solution to prepare the binder liquid. Although the granulation time is shortened, a high concentration of ethanol solution is required. The present invention only uses purified water to prepare the binder to obtain a 2% hydroxypropyl methylcellulose aqueous solution. By using the prescription of the present invention and appropriately extending the liquid addition and granulation time, particles with good fluidity, relatively concentrated distribution and good compressibility can also be obtained, thereby obtaining tablets with good properties and stable and reliable quality.
[0086] By comparing the content uniformity data, it is found that the content uniformity of the product prepared in this example is better than that of the original preparation, the value ratio of A+2.2S is smaller than that of the original product, and the product content is more uniform.
[0087]
[0088]
[0089] Comparison of influencing factors with the original formulation
[0090] According to the fourth part of the 2020 edition of the Chinese Pharmacopoeia, "9001 Guidelines for Stability Testing of Drug Substances and Preparations", the influencing factor test was conducted under high temperature, high humidity and light conditions to investigate the stability of the original preparation and the product of the present invention, and the content of related substances of the example and the original preparation of iguratimod was detected. The results are as follows. The data show that the stability of the product of this example is basically consistent with that of the original preparation.
[0091]
[0092] Comparison of dissolution curve with the original preparation
[0093] Determination method: Referring to the second method of "0931 Dissolution and Release Determination Method" in Part 4 of the 2020 edition of the "Chinese Pharmacopoeia", 900 ml of pH 7.8 phosphate buffer and pH 7.4 phosphate buffer were used as dissolution media, respectively. The test was carried out at 37°C and 50 rpm. 10 ml of samples were taken at 5, 10, 15, 30, 45, 60, 90, and 120 minutes, respectively. 4 ml was filtered through a 0.45 μm filter membrane, and the filtrate was taken for liquid phase detection.
[0094] By comparing the dissolution curve results of the embodiment and the original preparation with the f2 factor, it can be found that the in vitro dissolution results of the embodiment and the original preparation are consistent and have a high similarity.
[0095] pH 7.8 phosphate buffer dissolution data
[0096]
[0097]
[0098] pH 7.4 phosphate buffer dissolution data
[0099]
Claims
1. An iguratimod tablet, characterized in that: The iguratimod tablets are prepared from the following raw materials in parts by weight: 25 parts of iguratimod, 59.50-80.50 parts of microcrystalline cellulose PH101, 27.20-36.80 parts of sodium starch glycolate, 3.83-5.18 parts of sodium lauryl sulfate, 55.25-74.75 parts of purified water, 1.70-2.30 parts of hypromellose E5, 42.50-57.50 parts of microcrystalline cellulose PH302, and 0.85-1.15 parts of magnesium stearate.
2. The method for preparing the iguratimod tablets according to claim 1, characterized in that: The following steps are involved: Iguratimod and microcrystalline cellulose PH101 were shaken to mix for the first premixing and added to the wet granulation pot; sodium lauryl sulfate and sodium carboxymethyl starch were sieved and dispersed and added to the wet granulation pot, stirring was started, and the second premixing was performed; Adding a hydroxypropyl methylcellulose E5 solution prepared with purified water to perform wet granulation; adding the wet granules into a preliminarily preheated fluidized bed drying pot to continuously fluidize and dry the wet granules; using a mobile wet-dry granulator to granulate the dried granules to obtain dry granules; The dry granules are added into a mixing bin of a hopper, microcrystalline cellulose PH302 and sodium starch glycolate are added in sequence for mixing, and then magnesium stearate is added for total mixing; the total mixed material is tableted using a rotary tablet press to obtain elamod tablets.
3. The method for preparing the iguratimod tablets according to claim 2, characterized in that: The preparation method of the hydroxypropyl methylcellulose E5 solution comprises: slowly adding hydroxypropyl methylcellulose E5 to purified water while continuously stirring to prepare a 2% hydroxypropyl methylcellulose solution; stirring the solution at an appropriate speed for not less than 1 hour, and taking out the solution after it is clear and transparent by naked eye observation.
4. The method for preparing the iguratimod tablets according to claim 2, characterized in that: The first premixing includes: adding the API into a bag, then adding microcrystalline cellulose PH101 into the bag, tightening the bag mouth, shaking and mixing, and then passing through a 60-mesh sieve for mixing once.
5. The method for preparing the iguratimod tablets according to claim 2, characterized in that: In the second premixing, the stirring frequency is 240-260 rpm, the shearing speed is 1800-2200 rpm, and the pot cover and the filter bag are knocked regularly during the process to fully mix the premixed materials. The mixing is for 10 minutes.
6. The method for preparing the iguratimod tablets according to claim 2, characterized in that: During the wet granulation process, the atomization pressure is turned on at 0.20-0.30 MPa, the stirring is turned on at 340-360 rpm, the shearing is turned on at 1800-2200 rpm, and the liquid addition time is controlled at 15-25 min; after the liquid addition is completed, granulation is continued for 2-8 min with the same parameters.
7. The method for preparing the iguratimod tablets according to claim 2, characterized in that: Add the wet granules into the pre-heated fluidized bed drying pot, turn on the heating and air supply, set the air supply temperature at 60-70℃ and the material temperature at 40-50℃, and continue fluidizing and drying the wet granules; during the process, continuously monitor the drying loss, and after drying to a moisture content of ≤5.0%, the material temperature drops to below 40℃ and is removed from the pot.
8. The method for preparing the iguratimod tablets according to claim 2, characterized in that: The dried granules were granulated using a mobile wet and dry granulator, the sieve aperture was 0.8-1.0 mm, and the granulation frequency was 30 Hz.
9. The method for preparing the iguratimod tablets according to claim 2, characterized in that: Add the dry granules into the mixing bin of the hopper, add microcrystalline cellulose PH302 and sodium starch glycolate in turn and mix, set the mixing frequency to 20 Hz, and the mixing time to 20 minutes. After completion, add magnesium stearate and continue mixing at the same frequency for 10 minutes. After completion, discharge the material.
10. The method for preparing the iguratimod tablets according to claim 2, characterized in that: In the tableting step, the feeding speed is set to 15-25 rpm, the turntable speed is 10-30 rpm, the tableting hardness is controlled at 80-90 N, the tablet weight difference is controlled at ±5%, and the friability is controlled within 1%.
